vs
Steris（STE）与思佳讯（SWKS）财务数据对比。点击上方公司名可切换其他公司
Steris的季度营收约是思佳讯的1.4倍（$1.5B vs $1.0B），Steris净利率更高（12.9% vs 7.6%，领先5.2%），Steris同比增速更快（9.2% vs 8.6%），思佳讯自由现金流更多（$339.0M vs $199.5M），过去两年Steris的营收复合增速更高（15.8% vs -0.5%）
Steris plc是一家美爱合资的医疗设备企业，专注于为美国医疗体系提供灭菌服务及外科手术相关产品。其实际运营总部位于美国俄亥俄州门托市，深耕医疗消毒、感染防控、手术耗材等领域，为医疗机构提供专业可靠的医疗解决方案。
思佳讯是总部位于美国加利福尼亚州尔湾的半导体企业，公司股票在纳斯达克全球精选市场挂牌交易，股票代码为SWKS，同时也是标普500指数的成分股之一，在全球射频半导体领域拥有较高市场地位。
STE vs SWKS — 直观对比
营收规模更大
STE
是对方的1.4倍
$1.0B
营收增速更快
STE
高出0.5%
8.6%
净利率更高
STE
高出5.2%
7.6%
自由现金流更多
SWKS
多$139.5M
$199.5M
两年增速更快
STE
近两年复合增速
-0.5%
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $1.0B |
| 净利润 | $192.9M | $79.2M |
| 毛利率 | 43.8% | 41.3% |
| 营业利润率 | 18.3% | 10.0% |
| 净利率 | 12.9% | 7.6% |
| 营收同比 | 9.2% | 8.6% |
| 净利润同比 | 11.2% | 15.3% |
| 每股收益（稀释后） | $1.96 | $0.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收STESWKS
| Q1 26 | — | $1.0B | ||
| Q4 25 | $1.5B | $1.1B | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.4B | $965.0M | ||
| Q1 25 | $1.5B | $953.2M | ||
| Q4 24 | $1.4B | $1.1B | ||
| Q3 24 | $1.3B | $1.0B | ||
| Q2 24 | $1.3B | $905.5M |
净利润STESWKS
| Q1 26 | — | $79.2M | ||
| Q4 25 | $192.9M | $141.4M | ||
| Q3 25 | $191.9M | — | ||
| Q2 25 | $177.4M | $105.0M | ||
| Q1 25 | $145.7M | $68.7M | ||
| Q4 24 | $173.5M | $162.0M | ||
| Q3 24 | $150.0M | $60.5M | ||
| Q2 24 | $145.4M | $120.9M |
毛利率STESWKS
| Q1 26 | — | 41.3% | ||
| Q4 25 | 43.8% | 40.7% | ||
| Q3 25 | 44.2% | — | ||
| Q2 25 | 45.1% | 41.6% | ||
| Q1 25 | 43.3% | 41.1% | ||
| Q4 24 | 44.5% | 41.4% | ||
| Q3 24 | 43.6% | 41.9% | ||
| Q2 24 | 44.7% | 40.2% |
营业利润率STESWKS
| Q1 26 | — | 10.0% | ||
| Q4 25 | 18.3% | 10.1% | ||
| Q3 25 | 18.2% | — | ||
| Q2 25 | 17.7% | 11.5% | ||
| Q1 25 | 14.6% | 10.2% | ||
| Q4 24 | 17.9% | 16.9% | ||
| Q3 24 | 16.5% | 5.8% | ||
| Q2 24 | 14.5% | 14.4% |
净利率STESWKS
| Q1 26 | — | 7.6% | ||
| Q4 25 | 12.9% | 12.9% | ||
| Q3 25 | 13.1% | — | ||
| Q2 25 | 12.8% | 10.9% | ||
| Q1 25 | 9.8% | 7.2% | ||
| Q4 24 | 12.7% | 15.2% | ||
| Q3 24 | 11.3% | 5.9% | ||
| Q2 24 | 11.4% | 13.4% |
每股收益（稀释后）STESWKS
| Q1 26 | — | $0.53 | ||
| Q4 25 | $1.96 | $0.95 | ||
| Q3 25 | $1.94 | — | ||
| Q2 25 | $1.79 | $0.70 | ||
| Q1 25 | $1.48 | $0.43 | ||
| Q4 24 | $1.75 | $1.00 | ||
| Q3 24 | $1.51 | $0.36 | ||
| Q2 24 | $1.46 | $0.75 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $423.7M | $1.6B |
| 总债务越低越好 | $1.9B | $496.6M |
| 股东权益账面价值 | $7.2B | $5.8B |
| 总资产 | $10.6B | $7.9B |
| 负债/权益比越低杠杆越低 | 0.27× | 0.09× |
8季度趋势，按日历期对齐
现金及短期投资STESWKS
| Q1 26 | — | $1.6B | ||
| Q4 25 | $423.7M | $1.4B | ||
| Q3 25 | $319.2M | — | ||
| Q2 25 | $279.7M | $1.3B | ||
| Q1 25 | $171.7M | $1.5B | ||
| Q4 24 | $155.2M | $1.7B | ||
| Q3 24 | $172.2M | $1.6B | ||
| Q2 24 | $198.3M | $1.3B |
总债务STESWKS
| Q1 26 | — | $496.6M | ||
| Q4 25 | $1.9B | $496.4M | ||
| Q3 25 | $1.9B | — | ||
| Q2 25 | $1.9B | $496.2M | ||
| Q1 25 | $1.9B | $995.1M | ||
| Q4 24 | $2.0B | $994.7M | ||
| Q3 24 | $2.2B | $994.3M | ||
| Q2 24 | $2.2B | $994.0M |
股东权益STESWKS
| Q1 26 | — | $5.8B | ||
| Q4 25 | $7.2B | $5.8B | ||
| Q3 25 | $7.0B | — | ||
| Q2 25 | $7.0B | $5.7B | ||
| Q1 25 | $6.6B | $5.9B | ||
| Q4 24 | $6.4B | $6.4B | ||
| Q3 24 | $6.6B | $6.3B | ||
| Q2 24 | $6.4B | $6.3B |
总资产STESWKS
| Q1 26 | — | $7.9B | ||
| Q4 25 | $10.6B | $7.9B | ||
| Q3 25 | $10.4B | — | ||
| Q2 25 | $10.4B | $7.7B | ||
| Q1 25 | $10.1B | $7.9B | ||
| Q4 24 | $10.0B | $8.3B | ||
| Q3 24 | $10.2B | $8.3B | ||
| Q2 24 | $10.1B | $8.2B |
负债/权益比STESWKS
| Q1 26 | — | 0.09× | ||
| Q4 25 | 0.27× | 0.09× | ||
| Q3 25 | 0.27× | — | ||
| Q2 25 | 0.27× | 0.09× | ||
| Q1 25 | 0.29× | 0.17× | ||
| Q4 24 | 0.32× | 0.16× | ||
| Q3 24 | 0.33× | 0.16× | ||
| Q2 24 | 0.35× | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $298.2M | $395.5M |
| 自由现金流经营现金流 - 资本支出 | $199.5M | $339.0M |
| 自由现金流率自由现金流/营收 | 13.3% | 32.7% |
| 资本支出强度资本支出/营收 | 6.6% | 5.5% |
| 现金转化率经营现金流/净利润 | 1.55× | 4.99× |
| 过去12个月自由现金流最近4个季度 | $917.1M | $1.1B |
8季度趋势，按日历期对齐
经营现金流STESWKS
| Q1 26 | — | $395.5M | ||
| Q4 25 | $298.2M | $200.0M | ||
| Q3 25 | $287.8M | — | ||
| Q2 25 | $420.0M | $314.2M | ||
| Q1 25 | $260.8M | $409.4M | ||
| Q4 24 | $332.8M | $377.2M | ||
| Q3 24 | $250.7M | $476.1M | ||
| Q2 24 | $303.7M | $273.4M |
自由现金流STESWKS
| Q1 26 | — | $339.0M | ||
| Q4 25 | $199.5M | $144.0M | ||
| Q3 25 | $201.3M | — | ||
| Q2 25 | $326.4M | $252.7M | ||
| Q1 25 | $189.9M | $370.9M | ||
| Q4 24 | $243.6M | $338.2M | ||
| Q3 24 | $148.8M | $393.3M | ||
| Q2 24 | $195.7M | $249.0M |
自由现金流率STESWKS
| Q1 26 | — | 32.7% | ||
| Q4 25 | 13.3% | 13.1% | ||
| Q3 25 | 13.8% | — | ||
| Q2 25 | 23.5% | 26.2% | ||
| Q1 25 | 12.8% | 38.9% | ||
| Q4 24 | 17.8% | 31.7% | ||
| Q3 24 | 11.2% | 38.4% | ||
| Q2 24 | 15.3% | 27.5% |
资本支出强度STESWKS
| Q1 26 | — | 5.5% | ||
| Q4 25 | 6.6% | 5.1% | ||
| Q3 25 | 5.9% | — | ||
| Q2 25 | 6.7% | 6.4% | ||
| Q1 25 | 4.8% | 4.0% | ||
| Q4 24 | 6.5% | 3.6% | ||
| Q3 24 | 7.7% | 8.1% | ||
| Q2 24 | 8.4% | 2.7% |
现金转化率STESWKS
| Q1 26 | — | 4.99× | ||
| Q4 25 | 1.55× | 1.41× | ||
| Q3 25 | 1.50× | — | ||
| Q2 25 | 2.37× | 2.99× | ||
| Q1 25 | 1.79× | 5.96× | ||
| Q4 24 | 1.92× | 2.33× | ||
| Q3 24 | 1.67× | 7.87× | ||
| Q2 24 | 2.09× | 2.26× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
STE
| Servicerevenues | $404.7M | 27% |
| Consumablerevenues | $387.1M | 26% |
| Applied Sterilization Technologies | $286.6M | 19% |
| Capitalequipmentrevenues | $272.1M | 18% |
| Life Science | $145.8M | 10% |
SWKS
| Sales Channel Through Intermediary | $915.6M | 88% |
| Sales Channel Directly To Consumer | $119.8M | 12% |
